Prospective of Medical Cost for HIV/AIDS for Sex and Age Group in Range 2012-2050: Case of Mexico

Dora E. Ledesma-Carrión[1], Lidia Hernández-Hernández[2], and María Teresa Leonor Muciño-Porras[3]

[1]Instituto Nacional de Estadística y Geografía (INEGI), Av. Patriotismo 711,
Col. San Juan Mixcoac, C.P. 03730, Del. Benito Juárez, México D.F., Tel.: 52781000, ext.1624
[2] Instituto Nacional de Estadística y Geografía (INEGI), Av. Patriotismo 711,
Col. San Juan Mixcoac, C.P. 03730, Del. Benito Juárez, México D.F., Tel.: 52781000, ext.1438
[3] Instituto Nacional de Estadística y Geografía (INEGI), Av. Patriotismo 711,
Col. San Juan Mixcoac, C.P. 03730, Del. Benito Juárez, México D.F., Tel.: 52781000, ext.1057

---**ABSTRACT**---
Medical costs are calculated for HIV/AIDS for all age groups of Mexican people and sex into range of 2012-2050. Probabilities of entrance or disease detection, in treatment and death are calculated for each age group and sex. The maximum probabilities for each case are 1.07% (15-19 and 25-44), 5.038% (25-29) and 0.0749% - 0.106% (45-49, 85+) for male. Analogously, for female are 0.147% (20-24), 0.903% (25-29) and 0.0723% - 1.283% (45-49, 85+), respectively. The in treatment costs are more expensive for women than man. The maximum number of people in treatment is between 25-29 years old, decreasing after 50 years of age because of death. The sickness appears in early age (0-4) years old (probabilities new cases: 0.0506% male, 0.0353% female).

KEYWORDS: medical costs, prospective, aging, health, HIV/AIDS.

I. INTRODUCTION

Recent studies show that the number of pregnancies and births to teenage mothers has increased in recent years. Also the number of relationships high risk is usual among adolescents and young people in Mexico[1],[5]. Also, domestic and sexual violence among adolescents and young people has been a constant in the country. Human trafficking for sexual slavery and customs of many indigenous communities to sell their daughters for a can of gasoline, oil or anything else to anyone who wants to buy.

This work shows the economic impact over a horizon of 2012-2050 of Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) in terms of percentages of gross domestic product (GDP), for the three scenarios: base, optimal and worse. The base scenario is calculated by adjusting a model AR(2)MA(2)[2] with weighting, the other two are given by experts and both depend on the effect of energy and labor reforms.

The available information is from public institutions: Ministry of Health (Secretaría de Salud, SS[3], [8], [9],[11]), National Population Council (Consejo Nacional de Población, CONAPO[12]), Mexican Institute of Social Security (Instituto Mexicano del Seguro Social, IMSS[4], [6], [7]), National Institute of Statistics and Geography (Instituto Nacional de Estadística y Geografía, INEGI[10]) and private: Mexican Association of Insurance Institutions (Asociación Mexicana de Instituciones de Seguros, AMIS) and hospitals.

Population projections by CONAPO whose methodology appears on the official website[12] and decadal cohort of number of patients and unit costs for some diseases IMSS beneficiaries were used[6], [7]. IMSS information is not showed by age group neither sex (patients in treatment). New cases information appears since 1980 up to 1990 by big age group and sex and 1991-2011 by age group. Deceased people by HIV/AIDS is presented by age and sex.

The cost of this disease is high for its treatment and its duration. As insured persons by IMSS represent 40% of the population, IMSS data are taken as sampling. The Mexican health system (SS) covers the following institutions: IMSS, Institute for Social Security and Services for State Workers (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, ISSSTE), Popular Insurance (Seguro Popular, SP-IMSS), Oil Company (Petróleos Mexicanos, PEMEX), Ministry of Defense (Secretaría de la Defensa Nacional, SEDENA), Ministry of Navy (Secretaría de Marina, SEMAR), private institutions and other public institutions, so the numbers of deaths and new cases are representative of the population.

II.   METHODOLOGY

The proposed model is stochastic[2] with entrance, in treatment and death probabilities by HIV/AIDS, population, number of patients and unitary cost at time t by age group and sex (stock).
The probabilities are calculated for each year, t, as

$$Pr(death; age; sex; t) = \frac{\text{\# death by the disease(age; sex; t)}}{\text{\# death by the disease(age; sex; t)}} \tag{1}$$

$$Pr(new\ cases; age; sex; t) = \frac{\text{\# new cases or \#detected disease(age; sex; t)}}{\text{\# death by the disease(age; sex; t)}} \tag{2}$$

$$Pr(+1; age; sex; t) = \frac{\text{\# death by the disease(age; sex; t)\# permanence or \#people who have survived the disease one more year(age; sex; t)}}{\text{\# death by the disease(age; sex; t)}} \tag{3}$$

The model diagram is showed in Figure 1. Several considerations must be taken by each patient's condition.

Deaths. It works with the records of the SS with respect to age, sex and cause key, excluding unspecified. It has the historical 1990 to 2011. Curve fitting are applied to these data by ordinary least-squares (OLS) after the transformation of equation (4). In most cases it is the exponential. The growth rates are denoted as λ's. Prospective is constructed following behavior given these rates, for 2012-2050 taken as input data 2011.
The correlation coefficient of curve fitting are showed in Table 1.

$$death_t = death_0 e^{\lambda t} \Rightarrow Ln(death_t) = Ln(death_0\ e^{\lambda t}) = Ln(death_0) + \lambda t \tag{4}$$

The equation (1) is calculated using both prospective, the population and the exponential behavior of deaths by HIV/AIDS. This latter based on the high correlation coefficients by age group and sex shown in Table 1.
Behavior of deaths was analyzed. The age groups 60+ (male) and 55+ (female) showed an exceptional exponential behavior with correlation coefficients greater than 87% for female and 89% for male.

New cases. From the database of the SS tables of major diseases are obtained by age group (<1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-44, 45-49, 50-59, 60-65 & 65+). Information was obtained from 1990-2011 data which its trend behavior and basic statistics (mean and standard deviation) was analyzed. In case non-trend was chosen to simulate an exponential growth between the extreme values for the entire period. As a base scenario was chosen the trend values as first option and minimum among all the options as second choice.
The equation (2) is calculated using both prospective, the population and the exponential behavior of new cases by HIV/AIDS.

For new cases exhibit this behavior with correlations of 90% (10-14) for women and 80% (15-19) for men in general. The probabilities of entrance, in treatment and death to HIV/AIDS are dynamics and they are different in each stage. Their dynamic changes are gotten by LSO. Table of these dynamic changes by age group are shown in the appendix.

In treatment. IMSS data were used to rebuild the intermediate years. The method Runge-Kuta was applied to the exponential growth rates per period. Then data were redistributed according to death rates of SS for age groups. Subsequently normalized with respect to the prospective of the IMSS. The initial value is the amount of the average proportion of deaths[1] by age group by sex (2003-2011) multiplied by the number of patients treated according to IMSS prospective.

Data from 2011 patients in treatment are obtained by extrapolating the values of 2012 compared to exponential growth rates (2012-2020) of its prospective. The cases of initial values are the maximum, minimum and average in the period. After these are distributed by age and sex as mentioned in the previous paragraph.

The equation (3) is calculated using both prospective, the population and the exponential behavior of in treatment patients by HIV/AIDS. As the number of in treatment patients are IMSS data (sample), these were analyzed and calculated their behavior and prospective of both beneficiaries of the IMSS and beneficiaries who have survived the disease one more year. Latter, the probabilities by age group by sex by each year were gotten applying equation (3). After, these probabilities were input to make inference to population.
The AMIS published in 2011 the morbidity rate of HIV/AIDS for each 10,000. See Table 2.

Redistribution by age group (2012-2050) can be calculated using standard growth rates (about the death) following the general prospective IMSS or initial value using any of the three values obtained from the ratios of deaths by group age by sex by disease (1990-2012): average, maximum or minimum. And from the initial value to apply the before mentioned growth rates. The scenarios I, II and III use the average, maximum and minimal values as initial value (2011), respectively.


Pr(new cases/age/sex/t): Entrance probability for age for sex at time t
Pr(+1/age/sex/t): Suffering a year over the disease probability by age by sex at time t
Pr(death/age/sex/t): Death probability by HIV/AIDS by age by sex at time t

Figure 1: Schematic model. Started CONAPO population projections estimated population with HIV/AIDS, new cases and dying from this disease from 2012 to 2050.

Table 1: Correlation coefficients for exponential behavior (Death)

age groups	male	female	age groups	male	female
0-4			45-49	0.26	0.48
5-9			50-54	0.54	0.76
10-14	0.00		55-59	0.51	0.87
15-19			60-64	0.89	0.91
20-24	0.25		65-69	0.96	0.94
25-29			70-74	0.96	
30-34		0.56	75-79	0.92	
35-39		0.01	80-84		0.73
40-44	0.61	0.13	85 +		

Table 2: Morbidity rate of breast cancer for each 10,000 (2011)

MALE		(N10-N19)	FEMALE		(N10-N19)
age group	Distribution of insured	VIH/AIDS	age group	Distribution of insured	VIH/AIDS
0-20	29%	1	0-20	26%	0
21-35	30%	16	21-35	33%	0
36-50	29%	69	36-50	29%	1
51-65	10%	75	51-65	10%	0
+ 65	2%	26	+ 65	1%	0
TOTAL	100%	187	TOTAL	100%	1
% cases/total cases		0.25%	% cases/total cases		0.00%

2.1 Gross Domestic Product scenarios: Basis, optimal and worse.

Base Scenario. Quarterly gross domestic product (GDP) data since 1996-I up to 2012-IV current prices are applied to AR(2)MA(2) model (Eq. (5)). Adjusted data are deflated to base year 2012.

$$GDP_t = 1.037568\, GDP_{t-2} + [AR(2) = 0.730942, MA(2) = -0.937709], \quad 1996 \le t \le 2012 \qquad (5)$$

From Table 3, AR process is stationary and ARMA model is invertible. The model presents positive serial correlation because of Durbin-Watson statistical is between 1 and 2. Covariance matrix values appear in Table 4.

Table 3: Statistical parameter of model AR(2)MA(2)

$R^2 = 98.99\%$	Inv. AR Root (0.85,-0.85)
	Inv. MA Root (0.97,-0.97)
$s_\epsilon = 3.66x10^8$	t-Student (433.15, 8.79, -23.86)
n = 64	D-W = 1.160196

Table 4: Covariance matrix of model AR(2)MA(2)

	GDP(-2)	AR(2)	MA(2)
GDP(-2)	5.74E-06	-7.41E-05	-2.26E-05
AR(2)	-7.41E-05	0.006918	-0.000999
MA(2)	-2.26E-05	-0.000999	0.001545

The increasing GDP was 2.5% (January 2013) fall dawn 1.7% (December 2013). Average rate in June 2014 was 3.1% (fall dawn up to 2.5%) and last semester is expected 1.7%. The government expects an increasing rates during 2015 between (2.5% - 3.5%). In 2016, rates could be of (3.0% - 3.1%) and in 2017-2050 of 3%. If energy and labor reforms are successful, the GDP growth rates could be of up to 7% from 2020. The GDP prospective is showed in the Figure 2.


Figure 2: Curves fitted for each scenarios of gross domestic product are showed.

Optimum scenario. Upper limits of the ranges of the above paragraph.

Worse scenario. Lower limits of the ranges of the above paragraph.

2.2 Probabilities of entrance, in treatment and death for HIV/AIDS.

Dynamics probabilities prospective by patient condition by age group by sex by year are gotten from IMSS prospective for in treatment patients (Table 5) and applied to Runge-Kutta approximation to reconstruction year by year. Late, death data historic distribution by age groups and their prospective and applied to Table 6 data. Maximal rate for male is 0.09923% and 0.02904% for female at 2012. These rates are larger for women as men throughout the period. NOTE: In the IMSS prospective of in treatment patients, their rates are increasing from 2031 to differences obtained from the analysis of historical data from 1990 to 2011.

Table 5: IMSS prospective for in treatment patients of HIV/AIDS

Increasing rates of in treatment patients for range[9], [10]:	
λ_1 2012-2020	3.9%
λ_2 2021-2030	1.3%
λ_3 2031-2040	−0.5%
λ_4 2041-2050	−1.6%
λ 2012-2050	0.6%

In the cases of death and new cases condition, dynamics probabilities prospective are fitted by LSO. SS data are age groups.

III.   RESULTS

From Figures 3 and 4, comparing two arbitrary years, 2019 and 2040, HIV/AIDS medical costs are higher for men than women about 0.0332% and 0.0247% of GDP, respectively, for base scenario. To worse scenario the differences are 0.0475% and 0.0453% for each reference year. To optimum scenario are 0.0420% and 0.0208%. All in absolute terms.

The difference between the result for 2019 for base and optimal scenarios is due to if the Energetic and Labour Reforms we realize then the benefits will be reflected to the people until 2020.

If the initial value of patients in 2011 is the historical minimum, the differences in medical costs versus maximum are 0.000434% (2019) and 0.000132% (2040) for male. For female, the costs differences are 0.003119% and 0.001771%, respectively. All in absolute terms.

For historical minimum initial value versus average initial value, the differences in medical costs for male are 0.00031% (2019) and 0.000113% (2040) and for female are 0.00141% (2019) and 0.000799%, respectively. All in absolute terms.

From Figures 5, 6 and 7, the medical costs represent 77.956% (2019) and 77.954% (2040) for 50+ years old male respect all disease population. For female, the costs are 63.076% and 63.077%, respectively.

The maximum number of people in treatment is between 25 and 29 years old. The sick HIV/AIDS.

Table 6: Probabilities by patient condition by sex and year (2012-2050)

| Proba-bilities	enter (all age groups)		in treatment (all age groups)		death (all age groups)		death (50 +)	
YEAR	male	female	male	female	male	female	male	female
2010	0.009%	0.002%	0.664%	0.162%	0.007%	0.002%	0.009%	0.002%
2011	0.007%	0.002%	0.661%	0.161%	0.008%	0.002%	0.008%	0.002%
2012	0.008%	0.002%	0.882%	0.219%	0.008%	0.002%	0.009%	0.002%
2013	0.009%	0.002%	0.899%	0.223%	0.008%	0.002%	0.009%	0.002%
2014	0.010%	0.002%	0.917%	0.227%	0.008%	0.002%	0.009%	0.002%
2015	0.011%	0.002%	0.936%	0.231%	0.008%	0.002%	0.009%	0.002%
2016	0.012%	0.003%	0.955%	0.235%	0.008%	0.002%	0.009%	0.002%
2017	0.014%	0.003%	0.975%	0.239%	0.008%	0.002%	0.009%	0.002%
2018	0.015%	0.003%	0.995%	0.242%	0.008%	0.002%	0.009%	0.002%
2019	0.017%	0.003%	1.015%	0.246%	0.008%	0.002%	0.009%	0.002%
2020	0.019%	0.004%	1.034%	0.250%	0.008%	0.002%	0.009%	0.003%
2021	0.021%	0.004%	1.025%	0.247%	0.008%	0.002%	0.010%	0.003%
2022	0.023%	0.005%	1.017%	0.244%	0.008%	0.002%	0.010%	0.003%
2023	0.026%	0.005%	1.008%	0.241%	0.008%	0.002%	0.010%	0.003%
2024	0.028%	0.006%	0.998%	0.238%	0.008%	0.002%	0.010%	0.003%
2025	0.031%	0.006%	0.987%	0.235%	0.008%	0.002%	0.010%	0.003%
2026	0.035%	0.007%	0.977%	0.232%	0.008%	0.002%	0.010%	0.003%
2027	0.039%	0.007%	0.966%	0.229%	0.008%	0.002%	0.010%	0.003%
2028	0.043%	0.008%	0.956%	0.226%	0.008%	0.002%	0.010%	0.003%
2029	0.047%	0.009%	0.945%	0.223%	0.008%	0.003%	0.010%	0.003%
2030	0.053%	0.010%	0.934%	0.220%	0.008%	0.003%	0.011%	0.003%
2031	0.058%	0.011%	0.907%	0.213%	0.009%	0.003%	0.011%	0.004%
2032	0.065%	0.012%	0.881%	0.207%	0.009%	0.003%	0.011%	0.004%
2033	0.072%	0.013%	0.855%	0.201%	0.009%	0.003%	0.011%	0.004%
2034	0.079%	0.015%	0.831%	0.195%	0.009%	0.003%	0.011%	0.004%
2035	0.088%	0.016%	0.807%	0.189%	0.009%	0.003%	0.011%	0.004%
2036	0.098%	0.018%	0.784%	0.183%	0.009%	0.003%	0.011%	0.004%
2037	0.108%	0.019%	0.761%	0.178%	0.009%	0.003%	0.011%	0.004%
2038	0.120%	0.021%	0.740%	0.173%	0.009%	0.003%	0.012%	0.005%
2039	0.133%	0.024%	0.719%	0.168%	0.009%	0.003%	0.012%	0.005%
2040	0.147%	0.026%	0.699%	0.163%	0.009%	0.003%	0.012%	0.005%
2041	0.164%	0.029%	0.672%	0.156%	0.009%	0.003%	0.012%	0.005%
2042	0.181%	0.031%	0.647%	0.150%	0.009%	0.003%	0.012%	0.005%
2043	0.201%	0.035%	0.622%	0.144%	0.009%	0.003%	0.012%	0.005%
2044	0.223%	0.038%	0.599%	0.139%	0.009%	0.004%	0.012%	0.006%
2045	0.247%	0.042%	0.576%	0.133%	0.009%	0.004%	0.013%	0.006%
2046	0.274%	0.046%	0.555%	0.128%	0.009%	0.004%	0.013%	0.006%
2047	0.304%	0.051%	0.534%	0.123%	0.009%	0.004%	0.013%	0.006%
2048	0.337%	0.056%	0.514%	0.119%	0.009%	0.004%	0.013%	0.006%
2049	0.373%	0.062%	0.495%	0.114%	0.009%	0.004%	0.013%	0.007%
2050	0.414%	0.068%	0.477%	0.110%	0.009%	0.004%	0.013%	0.007%

Figure 3: Medical cost as a percentage of GDP for male and female since 2012 up to 2050 for three scenarios: base, optimum and worse.

The maximum number of people in treatment is between 25 and 29 years old. The disease appears in early age, 0-4 years old.


Figure 4: Medical cost as a percentage of GDP for male and female for base scenario.

Figure 5: Comparative number of patients for male and female by age group for base scenario and minimum initial value.


Figure 6: Comparative unit cost for male and female all age group vs. 50 and more years old.

Figure 7: Comparative number of patients of HIV/AIDS for male and female all age group vs. 50 and more years old.

IV. CONCLUSIONS

The HIV/AIDS is an expensive disease because of treatment cost. It is more expensive for male than woman. It is cheaper than diabetes mellitus[13] and breast cancer (for female) [14] but more expensive for genitourinary cancer[15], hypertensive diseases and renal failure (chronic-degenerative disease). The difference is because of in treatment time or survive time.

It is necessary to construct consistent data bases for new cases and in treatment condition patient for age by sex by year to better models.

1. Appendix

Table 7: Probabilities of enter or disease detection – Male

Age Group/ Year	2012	2015	2020	2025	2030	2035	2040	2045	2050
0-4	0.001%	0.001%	0.002%	0.003%	0.005%	0.010%	0.017%	0.029%	0.051%
5-9	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.004%	0.006%	0.011%
10-14	0.000%	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.004%	0.008%
15-19	0.002%	0.002%	0.004%	0.007%	0.012%	0.020%	0.035%	0.061%	0.107%
20-24	0.009%	0.012%	0.021%	0.037%	0.064%	0.113%	0.197%	0.342%	0.597%
25-29	0.018%	0.024%	0.040%	0.069%	0.117%	0.201%	0.352%	0.614%	1.070%
30-34	0.018%	0.024%	0.040%	0.069%	0.117%	0.201%	0.352%	0.614%	1.070%
35-39	0.018%	0.024%	0.040%	0.069%	0.117%	0.201%	0.352%	0.614%	1.070%
40-44	0.018%	0.024%	0.040%	0.069%	0.117%	0.201%	0.352%	0.614%	1.070%
45-49	0.012%	0.015%	0.023%	0.039%	0.066%	0.111%	0.184%	0.316%	0.551%
50-54	0.007%	0.009%	0.014%	0.021%	0.035%	0.058%	0.098%	0.163%	0.274%
55-59	0.007%	0.009%	0.014%	0.021%	0.035%	0.058%	0.098%	0.163%	0.274%
60-64	0.005%	0.006%	0.008%	0.012%	0.018%	0.028%	0.047%	0.079%	0.131%
65-69	0.002%	0.003%	0.004%	0.006%	0.008%	0.012%	0.018%	0.027%	0.043%
70-74	0.002%	0.003%	0.004%	0.006%	0.008%	0.012%	0.018%	0.027%	0.043%
75-79	0.002%	0.003%	0.004%	0.006%	0.008%	0.012%	0.018%	0.027%	0.043%
80-84	0.002%	0.003%	0.004%	0.006%	0.008%	0.012%	0.018%	0.027%	0.043%
85 +	0.002%	0.003%	0.004%	0.006%	0.008%	0.012%	0.018%	0.027%	0.043%

Table 8: Probabilities of enter or disease detection – Female

Age Group/ Year	2012	2015	2020	2025	2030	2035	2040	2045	2050
0-4	0.001%	0.001%	0.001%	0.002%	0.004%	0.007%	0.012%	0.021%	0.035%
5-9	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.003%	0.006%	0.010%
10-14	0.000%	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.003%	0.005%
15-19	0.001%	0.001%	0.002%	0.003%	0.005%	0.009%	0.015%	0.026%	0.044%
20-24	0.002%	0.003%	0.006%	0.010%	0.017%	0.029%	0.050%	0.085%	0.147%
25-29	0.003%	0.004%	0.007%	0.012%	0.020%	0.033%	0.057%	0.098%	0.167%
30-34	0.003%	0.004%	0.007%	0.012%	0.020%	0.033%	0.057%	0.098%	0.167%
35-39	0.003%	0.004%	0.007%	0.012%	0.020%	0.033%	0.057%	0.098%	0.167%
40-44	0.003%	0.004%	0.007%	0.012%	0.020%	0.033%	0.057%	0.098%	0.167%
45-49	0.002%	0.002%	0.004%	0.006%	0.010%	0.016%	0.027%	0.045%	0.077%
50-54	0.002%	0.002%	0.003%	0.004%	0.006%	0.011%	0.017%	0.029%	0.047%
55-59	0.002%	0.002%	0.003%	0.004%	0.006%	0.011%	0.017%	0.029%	0.047%
60-64	0.001%	0.001%	0.002%	0.002%	0.003%	0.005%	0.008%	0.013%	0.021%
65-69	0.000%	0.000%	0.000%	0.001%	0.001%	0.001%	0.002%	0.003%	0.005%
70-74	0.000%	0.000%	0.000%	0.001%	0.001%	0.001%	0.002%	0.003%	0.005%
75-79	0.000%	0.000%	0.000%	0.001%	0.001%	0.001%	0.002%	0.003%	0.005%
80-84	0.000%	0.000%	0.000%	0.001%	0.001%	0.001%	0.002%	0.003%	0.005%
85 +	0.000%	0.000%	0.000%	0.001%	0.001%	0.001%	0.002%	0.003%	0.005%

Table 9: Probabilities of stock or in treatment – Male

Age Group/ Year	2012	2015	2020	2025	2030	2035	2040	2045	2050
0-4	0.342%	0.365%	0.407%	0.396%	0.386%	0.345%	0.308%	0.259%	0.219%
5-9	0.037%	0.040%	0.044%	0.043%	0.042%	0.037%	0.033%	0.028%	0.024%
10-14	0.013%	0.014%	0.016%	0.015%	0.015%	0.012%	0.010%	0.008%	0.008%
15-19	0.108%	0.115%	0.128%	0.125%	0.122%	0.109%	0.097%	0.082%	0.069%
20-24	1.666%	1.777%	1.979%	1.929%	1.879%	1.678%	1.497%	1.263%	1.065%
25-29	4.240%	4.524%	5.038%	4.909%	4.784%	4.270%	3.812%	3.214%	2.710%
30-34	2.597%	2.770%	3.085%	3.007%	2.930%	2.615%	2.334%	1.968%	1.660%
35-39	1.233%	1.315%	1.465%	1.427%	1.391%	1.241%	1.108%	0.934%	0.788%
40-44	0.641%	0.684%	0.762%	0.742%	0.723%	0.646%	0.576%	0.486%	0.410%
45-49	0.323%	0.345%	0.384%	0.374%	0.364%	0.325%	0.290%	0.245%	0.206%
50-54	0.140%	0.149%	0.166%	0.162%	0.158%	0.141%	0.126%	0.106%	0.089%
55-59	0.073%	0.078%	0.087%	0.085%	0.083%	0.074%	0.066%	0.055%	0.047%
60-64	0.010%	0.011%	0.012%	0.012%	0.011%	0.010%	0.009%	0.008%	0.006%
65-69	0.007%	0.007%	0.008%	0.008%	0.008%	0.007%	0.006%	0.005%	0.004%
70-74	0.005%	0.005%	0.005%	0.005%	0.005%	0.005%	0.004%	0.003%	0.003%
75-79	0.004%	0.004%	0.005%	0.005%	0.005%	0.004%	0.004%	0.003%	0.003%
80-84	0.002%	0.002%	0.003%	0.003%	0.003%	0.002%	0.002%	0.002%	0.001%
85 +	0.008%	0.008%	0.009%	0.009%	0.009%	0.008%	0.007%	0.006%	0.005%

Table 10: Probabilities of stock or in treatment – Female

Age Group/ Year	2012	2015	2020	2025	2030	2035	2040	2045	2050
0-4	0.379%	0.405%	0.451%	0.439%	0.428%	0.382%	0.341%	0.287%	0.242%
5-9	0.049%	0.053%	0.059%	0.057%	0.056%	0.050%	0.044%	0.038%	0.032%
10-14	0.011%	0.012%	0.013%	0.013%	0.013%	0.011%	0.010%	0.008%	0.007%
15-19	0.048%	0.051%	0.057%	0.056%	0.054%	0.048%	0.043%	0.036%	0.031%
20-24	0.474%	0.506%	0.564%	0.549%	0.535%	0.478%	0.426%	0.360%	0.303%
25-29	0.760%	0.811%	0.903%	0.880%	0.858%	0.766%	0.683%	0.576%	0.486%
30-34	0.426%	0.454%	0.506%	0.493%	0.480%	0.429%	0.383%	0.323%	0.272%
35-39	0.262%	0.279%	0.311%	0.303%	0.295%	0.263%	0.235%	0.198%	0.167%
40-44	0.170%	0.181%	0.202%	0.197%	0.192%	0.171%	0.153%	0.129%	0.109%
45-49	0.074%	0.079%	0.088%	0.086%	0.084%	0.075%	0.067%	0.056%	0.047%
50-54	0.026%	0.028%	0.031%	0.030%	0.030%	0.026%	0.024%	0.020%	0.017%
55-59	0.012%	0.013%	0.015%	0.014%	0.014%	0.012%	0.011%	0.009%	0.008%
60-64	0.004%	0.004%	0.005%	0.005%	0.004%	0.004%	0.004%	0.003%	0.003%
65-69	0.002%	0.002%	0.003%	0.003%	0.002%	0.002%	0.002%	0.002%	0.001%
70-74	0.002%	0.002%	0.002%	0.002%	0.002%	0.002%	0.002%	0.001%	0.001%
75-79	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.000%
80-84	0.002%	0.002%	0.002%	0.002%	0.002%	0.002%	0.001%	0.001%	0.001%
85 +	0.001%	0.002%	0.002%	0.002%	0.002%	0.001%	0.001%	0.001%	0.001%

Table 11: Probabilities of death – Male

Age Group/ Year	2012	2015	2020	2025	2030	2035	2040	2045	2050
0-4	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.002%	0.002%	0.003%
5-9	0.000%	0.000%	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.003%
10-14	0.000%	0.000%	0.000%	0.000%	0.000%	0.000%	0.001%	0.001%	0.001%
15-19	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.002%
20-24	0.004%	0.005%	0.005%	0.005%	0.006%	0.007%	0.007%	0.008%	0.009%
25-29	0.013%	0.013%	0.013%	0.013%	0.014%	0.015%	0.016%	0.017%	0.018%
30-34	0.017%	0.018%	0.018%	0.018%	0.019%	0.020%	0.021%	0.023%	0.024%
35-39	0.017%	0.017%	0.018%	0.018%	0.018%	0.019%	0.020%	0.021%	0.022%
40-44	0.017%	0.018%	0.020%	0.024%	0.027%	0.031%	0.037%	0.044%	0.053%
45-49	0.016%	0.017%	0.019%	0.024%	0.030%	0.037%	0.046%	0.058%	0.075%
50-54	0.012%	0.012%	0.013%	0.015%	0.019%	0.023%	0.028%	0.033%	0.041%
55-59	0.009%	0.009%	0.010%	0.011%	0.013%	0.015%	0.018%	0.022%	0.027%
60-64	0.007%	0.007%	0.007%	0.007%	0.008%	0.008%	0.009%	0.011%	0.013%
65-69	0.008%	0.008%	0.010%	0.011%	0.014%	0.017%	0.022%	0.029%	0.041%
70-74	0.005%	0.005%	0.006%	0.006%	0.006%	0.007%	0.007%	0.008%	0.010%
75-79	0.004%	0.005%	0.006%	0.008%	0.010%	0.012%	0.016%	0.021%	0.028%
80-84	0.002%	0.003%	0.005%	0.007%	0.010%	0.014%	0.019%	0.028%	0.041%
85 +	0.003%	0.004%	0.006%	0.010%	0.017%	0.027%	0.043%	0.067%	0.106%

Table 12: Probabilities of death - Female

Age Group/ Year	2012	2015	2020	2025	2030	2035	2040	2045	2050
0-4	0.000%	0.000%	0.001%	0.001%	0.001%	0.001%	0.001%	0.002%	0.002%
5-9	0.000%	0.000%	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.003%
10-14	0.000%	0.000%	0.000%	0.000%	0.001%	0.001%	0.002%	0.002%	0.004%
15-19	0.000%	0.000%	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%	0.001%
20-24	0.001%	0.001%	0.001%	0.001%	0.002%	0.002%	0.002%	0.002%	0.003%
25-29	0.003%	0.003%	0.003%	0.003%	0.004%	0.004%	0.005%	0.005%	0.006%
30-34	0.003%	0.003%	0.004%	0.004%	0.005%	0.006%	0.007%	0.008%	0.010%
35-39	0.003%	0.003%	0.004%	0.004%	0.005%	0.006%	0.007%	0.008%	0.010%
40-44	0.004%	0.004%	0.006%	0.008%	0.010%	0.014%	0.020%	0.028%	0.039%
45-49	0.003%	0.003%	0.005%	0.007%	0.011%	0.018%	0.028%	0.044%	0.072%
50-54	0.002%	0.002%	0.003%	0.004%	0.005%	0.007%	0.010%	0.015%	0.021%
55-59	0.002%	0.002%	0.002%	0.003%	0.003%	0.003%	0.004%	0.005%	0.007%
60-64	0.001%	0.001%	0.002%	0.002%	0.002%	0.003%	0.003%	0.005%	0.006%
65-69	0.001%	0.001%	0.002%	0.003%	0.003%	0.005%	0.007%	0.010%	0.016%
70-74	0.001%	0.002%	0.002%	0.003%	0.004%	0.007%	0.010%	0.015%	0.024%
75-79	0.001%	0.001%	0.001%	0.002%	0.003%	0.004%	0.007%	0.011%	0.018%
80-84	0.001%	0.001%	0.001%	0.001%	0.002%	0.002%	0.003%	0.003%	0.004%
85 +	0.001%	0.002%	0.005%	0.013%	0.034%	0.087%	0.212%	0.517%	1.283%

V.   ACKNOWLEDGMENT

REFERENCES

[1]   (CELADE) - División de Población de la CEPAL, "Guideliness for the modules making on aging in the dwelling surveys. Latinoamerican and Caribean Center of Demography [Directrices para la elaboración de módulos sobre envejecimiento en las encuestas de hogares Centro Latinoamericano y Caribeño de Demografía]," Publicación de las Naciones Unidas, ISSN versión impresa 1680-886x ISSN versión electrónica 1680-8878 ISBN: 978-92-1-323244-6 LC/L.2969-P N° de venta: S.08.II.G.81, Santiago de Chile, noviembre de 2008.

[2]   Prajneshu, "Diffusion approximations for models of population growth with logarithmic interactions," Stochastic Processes and their application, Vol. 10 pp. 87-99, North-Holland Publishing Company, 1980.

[3]   Secretaría de Salud, "The mortality in Mexico 2000-2004, avoidable deaths: magnitude, distribution and trends [La mortalidad en México, 2000-2004. Muertes Evitables: magnitud, distribución y tendencias]", Subsecretaría de Innovación y Calidad Dirección General de Información en Salud, México, 2006.

[4]   Villarreal-Ríos Enrique, Campos Esparza Maribel, Galicia Rodríguez Liliana, Martínez González Lidia, Vargas Daza Emma Rosa, Torres Labra Guadalupe, Patiño Vega Adolfo, Rivera Martínez María Teresa, Aparicio Rojas Raúl, Juárez Durán Martín, "Annual cost per capital in the first attention level by gender [Costo anual per cápita en primer nivel de atención por género]," Unidad de Investigación Epidemiológica y en Servicios de Salud Querétaro, Instituto Mexicano del Seguro Social, Ciencia y Saúde Coletiva, 16(3):1961-1968, 2011.

[5]   Academia Nacional de Medicina de México, Academia Mexicana de Cirugía, Instituto de Geriatría, Universidad Nacional Autónoma de México, "Aging and health: a proposal for and action plan [Envejecimiento y salud: una propuesta para un plan de acción]," UNAM, México, 2012.

[6]   Instituto Mexicano del Seguro Social, "Finantial and actuarial report on December 31, 2009. [Informe Financiero y Actuarial al 31 de Diciembre de 2009.]"

[7]   Instituto Mexicano del Seguro Social, "Finantial and actuarial report on December 31, 2010. [Informe Financiero y Actuarial al 31 de Diciembre de 2010.]"

[8]   Secretaría de Salud, Sistema Nacional de Información en Salud, Dirección de Registros Administrativos, Departamento Explotación de Información Estadística, "Statistical yearbooks, Mexico, 2013. [Anuarios estadísticos. México, 2013.]," web site

(http://www.sinais.salud.gob.mx/basesdedatos/),11/04/2013, http://www.sinais.salud.gob.mx/publicaciones/anuario.html. The National health information system (Sistema Nacional de Información en Salud, SINAI) presents in its official web site statistical yearbooks, newsletters statistical information, mortality and morbidity data, health accounts, health situation in Mexico (basic indicators), executive summaries, guides and manuals and other publications.

[9]   Secretaría de Salud, Dirección General de Epidemiología, "Morbility yearbooks, Mexico, 2013. [Anuarios de Morbilidad México 2013.]," DE (ver http://www.dgsi.salud.gob.mx), 11/04/2013. The General Management of Statistical Information (Dirección General de Información en Salud, DGIS) shows in its official web site demographics data and population projections and dynamic cubes to extract the necessary data.

[10]   Estudio Nacional de Salud y Envejecimiento en México (ENASEM) 2001 Documento Metodológico, Sistema de Cuentas Nacionales de México, "Satellite account of the health sector of Mexico 2008-2010 [Cuenta satélite del sector salud de México 2008-2010]," INEGI, ISBN 978-607-494-316-0, México, 2012.

[11]   Secretaría de Salud, "Historical information of vital statistics births and deaths 1893-2010 [Información histórica de estadísticas vitales nacimientos y defunciones 1893-2010]," Dirección General de Epidemiología, Subsecretaria de Prevención y Promoción de la Salud, ISBN 978-607-460-235-7, México, 2011.

[12]   Database CONAPO, see link: http://www.conapo.gob.mx/es/CONAPO/Proyecciones Datos. The population projections of CONAPO are published along with demographic basic indicators and death data in its official web site.

[13]   Ledesma-Carrión Dora E., Hernández-Hernández L., Muciño-Porras María T.L., Prospective of Medical Cost for Diabetes Mellitus for Sex and Age Group in Range 2012-2050: Case of Mexico, Proceedings of the International MultiConference of Engineers and Computer Scientists 2015, Vol I, pp.67-72, ISBN: 978-988-19253-9-8, ISSN: 2078-0958 (Print);ISSN: 2078-0966 (Online), 2015.

[14]   Ledesma-Carrión Dora E., Hernández-Hernández L., Muciño-Porras María T.L., Prospective of Medical Cost for Breast Cancer for Sex and Age Group in Range 2012-2050: Case of Mexico, International Journal of Science and Research (IJSR) 2015, Vol 4 issue 7, pp.5-11, ISSN: 2319-7064 (Online), 2015.

[15]   Ledesma-Carrión Dora E., Hernández-Hernández L., Muciño-Porras María T.L., Prospective of Medical Cost for Genitourinary Cancer for Sex and Age Group in Range 2012-2050: Case of Mexico, International Journal of Emerging Trents in Science and Technology (IJETST) 2015, Vol 2 issue 6, pp.2717-2725, ISSN: 2348-9480 (Online), 2015.

Author Profile

Dora Elena Ledesma-Carrión received the degree in Physics, M.Sc. and PhD degrees in Engineering from Universidad Nacional Autónoma Nacional de México in 1986, 1997 and 2004, respectively. She has worked in the government institutions from 1986. Also she has advised different companies. Lines of investigation are operations research and materials science.

María Teresa Leonor Muciño Porras Degree in Actuarial Science from UNAM. Has worked in both the public administration and private enterprise among its main achievements are the Methodological Guide for Collecting Information, Manual of sociodemographic indicators coordinate work to understand the impact of the downgrade of the Electoral Roll through demographic indicators.

Lidia Hernández Hernández Degree in Physics and Mathematics of IPN, Master in Engineering from UNAM. She has worked in public administration and teaching. Lines of investigation are applied mathematics.